ERBB2 and neoplasm: Studies have shown that the combined therapy can affect the tumor microenvironment, increase the response rate of tumor cells to targeted drugs, and ultimately improve disease control.111 Encouragingly, ramucirumab has been approved as a second-line treatment for EAC, while trastuzumab has been approved for first-line treatment in combination with chemotherapy in HER-2-positive patients.